exhibit 10.1

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***],
HAS BEEN OMITTED BECAUSE GERON Corporation HAS DETERMINED THE INFORMATION (I) IS
NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO GERON Corporation
IF PUBLICLY DISCLOSED.

CHANGE ORDER #1

Client Name:

GERON Corporation

Drug Name or Number:

Imetelstat

Protocol Number:

63935937MDS3001

Parexel Project Number:

[***]

Change Order Number:

1

Change Order Date:

June 19, 2019

Parexel Project Manager:

[***]

Parexel and Client signed a Work Order dated January 30, 2019.  The parties wish
to amend said Work Order as applicable and hereby agree as follows:

1.

The items listed on Change in Scope Log #1, attached as Attachment 1 to this
Change Order, dated June 19, 2019 shall be incorporated in said Work Order.

2.

The total contract value changes as follows:

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

3.

Section 7 of the Work Order shall be replaced in its entirety with the
following:

Parexel Key Personnel.  The following Parexel Key Personnel, as defined in
Section 2.5 of the Agreement, are assigned to the Project covered by this Work
Order:

Title

Name

Telephone Number

Email

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***],
HAS BEEN OMITTED BECAUSE GERON CORPORATION HAS DETERMINED THE INFORMATION (I) IS
NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO GERON CORPORATION
IF PUBLICLY DISCLOSED.

 

Page 1 of 38

--------------------------------------------------------------------------------

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

4.

Section 8 of the Work Order shall be replaced in its entirety with the
following:

Parexel Sub-Processors.  The following Parexel Sub-Processors, as defined in
Attachment E of the Agreement, are assigned to the Project:

 

•

[***]

 

•

[***]

 

•

[***]

 

•

[***]

 

•

[***]

 

•

[***]

 

•

[***]

 

•

[***]

 

•

[***]

 

•

[***]

 

•

[***]

 

•

[***]

 

•

[***]

 

•

[***]

 

•

[***]

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***],
HAS BEEN OMITTED BECAUSE GERON CORPORATION HAS DETERMINED THE INFORMATION (I) IS
NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO GERON CORPORATION
IF PUBLICLY DISCLOSED.

 

Page 2 of 38

--------------------------------------------------------------------------------

 

 

•

[***]

 

•

[***]

 

•

[***]

 

•

[***]

 

•

[***]

 

•

[***]

 

Any changes to Sub-Processors shall be made pursuant to Sections 7.4 and 7.5 of
Attachment E.

5.

The Specifications and Assumptions Exhibit A in the Work Order shall be replaced
in its entirety by Attachment 2 in this Change Order #1.

6.

The Task and Responsibility Exhibit B in the Work Order shall be replaced in its
entirety by Attachment 3 in this Change Order #1.

7.

The Budget Grid Summary in Exhibit F in the Work Order shall be replaced in its
entirety by Attachment 4 in this Change Order #1.

8.

The [***] Payment Schedule in Exhibit G in the Work Order shall be replaced in
its entirety by Attachment 5 in this Change Order #1.

No term or condition other than the above shall be amended by this Change
Order.  

[Signatures on following page]

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***],
HAS BEEN OMITTED BECAUSE GERON CORPORATION HAS DETERMINED THE INFORMATION (I) IS
NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO GERON CORPORATION
IF PUBLICLY DISCLOSED.

 

Page 3 of 38

--------------------------------------------------------------------------------

 

 

GERON Corporation

Parexel International (IRL) Limited

By: /s/ Andrew J. Grethlein

By:  /s/ Mark Fives

Name: Andrew J. Grethlein, Ph.D.

Name:  Mark Fives

Title: Executive Vice President and Chief

Business Officer

Title:  Senior Manager

Date:  19-Jun-2019

Date:  20-Jun-2019

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***],
HAS BEEN OMITTED BECAUSE GERON CORPORATION HAS DETERMINED THE INFORMATION (I) IS
NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO GERON CORPORATION
IF PUBLICLY DISCLOSED.

 

Page 4 of 38

--------------------------------------------------------------------------------

 

ATTACHMENT 1

CHANGE IN SCOPE LOG 1

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***],
HAS BEEN OMITTED BECAUSE GERON CORPORATION HAS DETERMINED THE INFORMATION (I) IS
NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO GERON CORPORATION
IF PUBLICLY DISCLOSED.

Page 5 of 38

--------------------------------------------------------------------------------

 

CHANGE IN SCOPE LOG

Change In Scope Log

 

 

 

 

 

 

 

 

Protocol No.

63935937MDS3001

 

 

 

 

Client Name

GERON Corporation

 

 

 

 

Parexel Project No.

[***]

 

 

 

 

Project Manager

[***]

 

 

 

 

CIS No.

1

 

 

 

 

Date

19-June-2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Item#

Date Requested and Requestor

CIS Task description

Service Fee (Contract Currency)

Investigator Fees

Pass Through Costs

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***],
HAS BEEN OMITTED BECAUSE GERON CORPORATION HAS DETERMINED THE INFORMATION (I) IS
NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO GERON CORPORATION
IF PUBLICLY DISCLOSED.

Page 6 of 38

 

 

--------------------------------------------------------------------------------

Parexel Project #[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***],
HAS BEEN OMITTED BECAUSE GERON CORPORATION HAS DETERMINED THE INFORMATION (I) IS
NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO GERON CORPORATION
IF PUBLICLY DISCLOSED.

Page 7 of 38

--------------------------------------------------------------------------------

Parexel Project #[***]

ATTACHMENT 2

SPECIFICATIONS AND ASSUMPTIONS

 

{7 pages omitted}

 

[***]

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***],
HAS BEEN OMITTED BECAUSE GERON CORPORATION HAS DETERMINED THE INFORMATION (I) IS
NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO GERON CORPORATION
IF PUBLICLY DISCLOSED.

Page 8 of 38

--------------------------------------------------------------------------------

Parexel Project #[***]

ATTACHMENT 3
TASKS & RESPONSIBILITIES

{21 pages omitted}

[***]

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***],
HAS BEEN OMITTED BECAUSE GERON CORPORATION HAS DETERMINED THE INFORMATION (I) IS
NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO GERON CORPORATION
IF PUBLICLY DISCLOSED.

Page 15 of 38

--------------------------------------------------------------------------------

Parexel Project #[***]

ATTACHMENT 4
Budget grid summary

Table 1 – Budget Grid Summary

[***]

 

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***],
HAS BEEN OMITTED BECAUSE GERON CORPORATION HAS DETERMINED THE INFORMATION (I) IS
NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO GERON CORPORATION
IF PUBLICLY DISCLOSED.

Page 36 of 38

--------------------------------------------------------------------------------

Parexel Project #[***]

ATTACHMENT 5
[***] PAYMENT SCHEDULE

{2 pages omitted}

[***]

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***],
HAS BEEN OMITTED BECAUSE GERON CORPORATION HAS DETERMINED THE INFORMATION (I) IS
NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO GERON CORPORATION
IF PUBLICLY DISCLOSED.

Page 37 of 38